JP2001510683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001510683A5 JP2001510683A5 JP2000502207A JP2000502207A JP2001510683A5 JP 2001510683 A5 JP2001510683 A5 JP 2001510683A5 JP 2000502207 A JP2000502207 A JP 2000502207A JP 2000502207 A JP2000502207 A JP 2000502207A JP 2001510683 A5 JP2001510683 A5 JP 2001510683A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- domain
- immunogen
- native epitope
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 description 43
- 230000002163 immunogen Effects 0.000 description 43
- 239000002253 acid Substances 0.000 description 34
- -1 amino Chemical group 0.000 description 34
- 230000014759 maintenance of location Effects 0.000 description 22
- 230000005945 translocation Effects 0.000 description 21
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 210000002925 A-like Anatomy 0.000 description 10
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 10
- 231100000252 nontoxic Toxicity 0.000 description 10
- 230000003000 nontoxic effect Effects 0.000 description 10
- 210000000172 cytosol Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 4
- 230000005859 cell recognition Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- MYCSPQIARXTUTP-SRVKXCTJSA-N Asn-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N MYCSPQIARXTUTP-SRVKXCTJSA-N 0.000 description 2
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 2
- NDKSHNQINMRKHT-PEXQALLHSA-N His-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N NDKSHNQINMRKHT-PEXQALLHSA-N 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- DXTYEWAQOXYRHZ-KKXDTOCCSA-N Ala-Phe-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N DXTYEWAQOXYRHZ-KKXDTOCCSA-N 0.000 description 1
- ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- UUERSUCTHOZPMG-SRVKXCTJSA-N Cys-Asn-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UUERSUCTHOZPMG-SRVKXCTJSA-N 0.000 description 1
- UPURLDIGQGTUPJ-ZKWXMUAHSA-N Cys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N UPURLDIGQGTUPJ-ZKWXMUAHSA-N 0.000 description 1
- PGBLJHDDKCVSTC-CIUDSAMLSA-N Cys-Met-Gln Chemical compound CSCC[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O PGBLJHDDKCVSTC-CIUDSAMLSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010032388 glycyl-prolyl-glycyl-arginyl-alanyl-phenylanine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101150084157 lrp-1 gene Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 244000079416 protozoan pathogen Species 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5237597P | 1997-07-11 | 1997-07-11 | |
| US60/052,375 | 1997-07-11 | ||
| PCT/US1998/014341 WO1999002713A1 (en) | 1997-07-11 | 1998-07-10 | Pseudomonas exotoxin a-like chimeric immunogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008316284A Division JP2009079068A (ja) | 1997-07-11 | 2008-12-11 | Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001510683A JP2001510683A (ja) | 2001-08-07 |
| JP2001510683A5 true JP2001510683A5 (enExample) | 2006-01-05 |
Family
ID=21977213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000502207A Pending JP2001510683A (ja) | 1997-07-11 | 1998-07-10 | Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原 |
| JP2008316284A Pending JP2009079068A (ja) | 1997-07-11 | 2008-12-11 | Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008316284A Pending JP2009079068A (ja) | 1997-07-11 | 2008-12-11 | Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8092809B2 (enExample) |
| EP (1) | EP1000163B1 (enExample) |
| JP (2) | JP2001510683A (enExample) |
| AT (1) | ATE307208T1 (enExample) |
| AU (1) | AU731703B2 (enExample) |
| CA (1) | CA2295971C (enExample) |
| DE (1) | DE69831951T2 (enExample) |
| DK (1) | DK1000163T3 (enExample) |
| ES (1) | ES2249838T3 (enExample) |
| WO (1) | WO1999002713A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1078988A1 (en) * | 1999-08-27 | 2001-02-28 | Academia Sinica | Pseudomonas fusion protein vaccines |
| US6838553B1 (en) * | 1999-10-05 | 2005-01-04 | Academia Sinica | Peptide repeat immunogens |
| EP1242122B1 (en) * | 1999-10-22 | 2009-09-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Delivery of proteins across polar epithelial cell layers |
| TWI293957B (en) * | 2004-07-21 | 2008-03-01 | Healthbanks Biotech Co Ltd | A superantigen fusion protein and the use thereof |
| US7964200B2 (en) | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
| US20090203884A1 (en) * | 2008-01-31 | 2009-08-13 | Healthbanks Biotech Co., Ltd. | Chimeric hiv fusion proteins as vaccines |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| CN109608550B (zh) * | 2012-12-05 | 2020-09-11 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
| US9861681B2 (en) | 2013-04-18 | 2018-01-09 | The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases | Therapeutic compositions for neutralizing type I interferons, and methods of use |
| CA2985381C (en) * | 2015-06-01 | 2020-03-24 | Reber Genetics Co., Ltd. | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases |
| PL3762009T3 (pl) | 2018-03-08 | 2022-09-12 | Applied Molecular Transport Inc. | Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego |
| SG11202104734YA (en) | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Cholix-derived carriers for oral delivery of heterologous payload |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| US6022950A (en) * | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| CA1289880C (en) * | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Anti-human ovarian cancer immunotoxins and methods of use thereof |
| US5082927A (en) * | 1986-09-24 | 1992-01-21 | The United States Of America As Represented By The Department Of Health And Human Services | Selectively cytotoxic IL-4-PE40 fusion protein |
| US6051405A (en) * | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
| US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US5206353A (en) * | 1988-07-23 | 1993-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | CD-4/cytotoxic gene fusions |
| CA1340530C (en) * | 1989-04-28 | 1999-05-04 | Kok Kheong Lee | Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics |
| US5980896A (en) * | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| AU657087B2 (en) * | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
| US5458878A (en) * | 1990-01-02 | 1995-10-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity |
| JP2665827B2 (ja) * | 1990-05-11 | 1997-10-22 | アメリカ合衆国 | 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素 |
| US5608039A (en) * | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| US6099842A (en) * | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
| US5328984A (en) * | 1991-03-04 | 1994-07-12 | The United States As Represented By The Department Of Health & Human Services | Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells |
| US5190873A (en) * | 1991-06-21 | 1993-03-02 | California Institute Of Biological Research | Hybrid tryptophan aporepressor containing ligand binding sites |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5935580A (en) * | 1992-04-21 | 1999-08-10 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
| CA2136724A1 (en) * | 1992-06-18 | 1993-12-23 | Ira H. Pastan | Recombinant pseudomonas exotoxin with increased activity |
| US6303120B1 (en) * | 1994-03-15 | 2001-10-16 | Memorial Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the lewis y epitope and uses thereof |
| US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| DK0759944T3 (da) | 1994-05-13 | 2001-11-26 | Biovation Ltd | Forbedringer af og relateret til peptidfremføring |
| US5573916A (en) * | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| DE69521331T2 (de) * | 1994-11-01 | 2001-09-20 | Winfried Wels | Nukleinsäure-einbringungssystem |
| US5843882A (en) * | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
| US5980895A (en) * | 1995-10-13 | 1999-11-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation |
| IL116559A (en) * | 1995-11-17 | 2005-11-20 | Yissum Res Dev Co | Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence |
| WO1997025068A2 (en) * | 1996-01-05 | 1997-07-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Mesothelin antigen and methods and kits for targeting it |
| US6426075B1 (en) * | 1996-11-06 | 2002-07-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Protease-activatable pseudomonas exotoxin A-like proproteins |
| US6086900A (en) * | 1997-03-26 | 2000-07-11 | Board Of Regents, The University Of Texas Systems | Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes |
| US20030054012A1 (en) * | 2000-05-12 | 2003-03-20 | Fitzgerald David J. | Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response |
| US6140066A (en) * | 1998-03-24 | 2000-10-31 | Lorberboum-Galski; Haya | Methods of cancer diagnosis using a chimeric toxin |
| US6090388A (en) * | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| EP1242122B1 (en) * | 1999-10-22 | 2009-09-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Delivery of proteins across polar epithelial cell layers |
| EP1224290B1 (en) * | 1999-10-22 | 2006-06-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Disulfide conjugated cell toxins and methods of making and using them |
| US6783761B2 (en) * | 2000-05-05 | 2004-08-31 | Aphton Corporation | Chimeric peptide immunogens |
| DK1379550T3 (da) * | 2000-12-21 | 2009-07-06 | Us Gov Health & Human Serv | Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser |
| EP1549144A4 (en) * | 2002-10-04 | 2010-01-06 | Univ California | METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE |
| WO2004033657A2 (en) * | 2002-10-07 | 2004-04-22 | Antigenics, Inc. | Heat shock protein binding fragments of cd91, and uses thereof |
| US7335361B2 (en) * | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
| WO2006041906A2 (en) * | 2004-10-04 | 2006-04-20 | Trinity Biosystems, Inc. | Methods and compositions for immunizing against pseudomonas infection |
| US8877714B2 (en) * | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
| WO2008118013A2 (en) * | 2007-03-23 | 2008-10-02 | To-Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
| US20100143920A1 (en) * | 2007-04-06 | 2010-06-10 | The Trustees Of The University Of Pennsylvania | Surfactant Protein D is a Biomarker for Steroid Responsiveness in Asthma and Chronic Obstructive Pulmonary Disease |
-
1998
- 1998-07-10 AT AT98935604T patent/ATE307208T1/de active
- 1998-07-10 EP EP98935604A patent/EP1000163B1/en not_active Expired - Lifetime
- 1998-07-10 JP JP2000502207A patent/JP2001510683A/ja active Pending
- 1998-07-10 DK DK98935604T patent/DK1000163T3/da active
- 1998-07-10 ES ES98935604T patent/ES2249838T3/es not_active Expired - Lifetime
- 1998-07-10 WO PCT/US1998/014341 patent/WO1999002713A1/en not_active Ceased
- 1998-07-10 AU AU84813/98A patent/AU731703B2/en not_active Ceased
- 1998-07-10 CA CA2295971A patent/CA2295971C/en not_active Expired - Fee Related
- 1998-07-10 DE DE69831951T patent/DE69831951T2/de not_active Expired - Lifetime
-
2007
- 2007-12-20 US US11/962,007 patent/US8092809B2/en not_active Expired - Fee Related
-
2008
- 2008-12-11 JP JP2008316284A patent/JP2009079068A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsuo et al. | Establishment of a foreign antigen secretion system in mycobacteria | |
| RU2248214C2 (ru) | Слитые белки с fc-фрагментом иммуноглобулина для повышения иммуногенности белковых и пептидных антигенов | |
| KR101650364B1 (ko) | 항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질 | |
| JP2003529319A (ja) | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 | |
| JPH10502523A (ja) | 変異型ｒドメインを有するジフテリア毒素ワクチン | |
| CN107847575B (zh) | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 | |
| US11352416B2 (en) | Mosaic chimeric viral vaccine particle | |
| EP1003851A2 (fr) | Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie | |
| AU8395991A (en) | Interleukin-2-leukotoxin gene fusions and uses thereof | |
| US5976544A (en) | Polypeptides and vaccines for Bordetellapertussis and method of use | |
| CA2295971A1 (en) | Pseudomonas exotoxin a-like chimeric immunogens | |
| AU4100800A (en) | Method for down-regulating il5 activity | |
| Zaghouani et al. | Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein. | |
| Löwenadler et al. | T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions | |
| JP3764476B2 (ja) | 組合せポリペプチド抗原 | |
| Bäckström et al. | Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli | |
| EP1090994B1 (en) | Peptide repeat immunogens | |
| JPS6117523A (ja) | 淋疾のための広域スペクトルワクチン | |
| Frenchick et al. | Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles | |
| KR100217809B1 (ko) | 재조합 bcg 백신 | |
| FitzGerald et al. | Characterization of V3 loop-Pseudomonas exotoxin chimeras: candidate vaccines for human immunodeficiency virus-1 | |
| Varona-Santos et al. | Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants | |
| JP2004509846A (ja) | 肝炎ｃ型ウイルスコンジュゲート | |
| CN100368436C (zh) | 人绒毛膜促性腺激素重组多表位嵌合肽cp22抗原的分子设计及其制备方法 | |
| CN101969998A (zh) | HIV p17蛋白的一种截短形式 |